C. Warren Olanow
Department of Neurology and Neuroscience
Mount Sinai School of Medicine
New York
NY 10029
USA
Name/email consistency: high
- The delayed-start study in Parkinson disease: can't satisfy everyone. Olanow, C.W., Rascol, O. Neurology (2010)
- A double-blind, delayed-start trial of rasagiline in Parkinson's disease. Olanow, C.W., Rascol, O., Hauser, R., Feigin, P.D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., Tolosa, E. N. Engl. J. Med. (2009)
- The scientific and clinical basis for the treatment of Parkinson disease (2009). Olanow, C.W., Stern, M.B., Sethi, K. Neurology (2009)
- Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Olanow, C.W., Gracies, J.M., Goetz, C.G., Stoessl, A.J., Freeman, T., Kordower, J.H., Godbold, J., Obeso, J.A. Mov. Disord. (2009)
- Dopaminergic transplantation for Parkinson's disease: current status and future prospects. Olanow, C.W., Kordower, J.H., Lang, A.E., Obeso, J.A. Ann. Neurol. (2009)
- Can we achieve neuroprotection with currently available anti-parkinsonian interventions?. Olanow, C.W. Neurology (2009)
- Is Parkinson's disease a prion disorder?. Olanow, C.W., Prusiner, S.B. Proc. Natl. Acad. Sci. U.S.A. (2009)
- Levodopa therapy for Parkinson's disease: challenges and future prospects. Olanow, C.W., Lees, A., Obeso, J. Mov. Disord. (2008)
- Levodopa/dopamine replacement strategies in Parkinson's disease--future directions. Olanow, C.W. Mov. Disord. (2008)
- A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Olanow, C.W., Hauser, R.A., Jankovic, J., Langston, W., Lang, A., Poewe, W., Tolosa, E., Stocchi, F., Melamed, E., Eyal, E., Rascol, O. Mov. Disord. (2008)
- Why have we failed to achieve neuroprotection in Parkinson's disease?. Olanow, C.W., Kieburtz, K., Schapira, A.H. Ann. Neurol. (2008)
- Tolcapone: an efficacy and safety review (2007). Olanow, C.W., Watkins, P.B. Clin. Neuropharmacol (2007)
- The pathogenesis of cell death in Parkinson's disease--2007. Olanow, C.W. Mov. Disord. (2007)
- TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Olanow, C.W., Schapira, A.H., LeWitt, P.A., Kieburtz, K., Sauer, D., Olivieri, G., Pohlmann, H., Hubble, J. Lancet. Neurol (2006)
- Movement disorders: a step in the right direction. Olanow, C.W. Lancet. Neurol (2006)
- Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. Olanow, C.W. Neurology (2006)
- Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Olanow, C.W., Obeso, J.A., Stocchi, F. Lancet. Neurol (2006)
- Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease. Olanow, C.W., Obeso, J.A., Stocchi, F. Nature Clinical Practice. Neurology (2006)
- Ubiquitin-proteasome system and Parkinson's disease. Olanow, C.W., McNaught, K.S. Mov. Disord. (2006)
- Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Olanow, C.W., Jankovic, J. Mov. Disord. (2005)
- Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. Schapira, A.H., Olanow, C.W. JAMA (2004)
- The scientific basis for the current treatment of Parkinson's disease. Olanow, C.W. Annu. Rev. Med. (2004)
- Manganese-induced parkinsonism and Parkinson's disease. Olanow, C.W. Ann. N. Y. Acad. Sci. (2004)
- Lewy-body formation is an aggresome-related process: a hypothesis. Olanow, C.W., Perl, D.P., DeMartino, G.N., McNaught, K.S. Lancet. Neurol (2004)
- Levodopa in the treatment of Parkinson's disease: current controversies. Olanow, C.W., Agid, Y., Mizuno, Y., Albanese, A., Bonuccelli, U., Bonucelli, U., Damier, P., De Yebenes, J., Gershanik, O., Guttman, M., Grandas, F., Hallett, M., Hornykiewicz, O., Jenner, P., Katzenschlager, R., Langston, W.J., LeWitt, P., Melamed, E., Mena, M.A., Michel, P.P., Mytilineou, C., Obeso, J.A., Poewe, W., Quinn, N., Raisman-Vozari, R., Rajput, A.H., Rascol, O., Sampaio, C., Stocchi, F. Mov. Disord. (2004)
- Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Olanow, C.W., Kieburtz, K., Stern, M., Watts, R., Langston, J.W., Guarnieri, M., Hubble, J. Arch. Neurol. (2004)
- Dietary vitamin E and Parkinson's disease: something to chew on. Olanow, C.W. Lancet. Neurol (2003)
- A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Olanow, C.W., Goetz, C.G., Kordower, J.H., Stoessl, A.J., Sossi, V., Brin, M.F., Shannon, K.M., Nauert, G.M., Perl, D.P., Godbold, J., Freeman, T.B. Ann. Neurol. (2003)
- Surgical therapy for Parkinson's disease. Olanow, C.W. Eur. J. Neurol. (2002)
- An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Olanow, C.W., Watts, R.L., Koller, W.C. Neurology (2001)
- Why delaying levodopa is a good treatment strategy in early Parkinson's disease. Olanow, C.W., Stocchi, F. Eur. J. Neurol. (2000)